HMG-CoA reductase inhibitor, simvastatin improves reverse cholesterol transport in type 2 diabetic patients with hyperlipidemia

Journal of Atherosclerosis and Thrombosis

Volumn 15, Issue 1, 2008, Pages 20-25

  Guan, Jing Zhi ^a   Tamasawa, Naoki ^a   Murakami, Hiroshi ^a   Matsui, Jun ^a   Tanabe, Jutaro ^a   Matsuki, Kota ^a   Yamashita, Maki ^a   Suda, Toshihiro ^a  

^a HIROSAKI UNIVERSITY   (Japan)

Author keywords

ABCA1; HDL C; Reverse cholesterol transport; Statin

Indexed keywords

APOLIPOPROTEIN A1; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SIMVASTATIN;

AGED; ARTICLE; BLOOD; FEMALE; GENE EXPRESSION; HUMAN; HYPERLIPIDEMIA; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS;

AGED; APOLIPOPROTEIN A-I; CHOLESTEROL; CHOLESTEROL, HDL; DIABETES MELLITUS, TYPE 2; FEMALE; GENE EXPRESSION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; MALE; MIDDLE AGED; SIMVASTATIN;

EID: 45149104138     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.E512     Document Type: Article

References (30)

1. Krauss RM: Lipids and lipoproteins in patients with type 2 diabetes. Diabetes Care, 2004; 27:1496-1504
2. Martin G, Duez H, Blanquart C, Berezowski V, Poulain P, Fruchart JC, Najib-Fruchart J, Glineur C, and Staels B: Statin-induced inhibition of the Rho-signaling pathway activates PPARα and induces HDL ApoA-I. J Clin Invest, 2001; 107:1423-1432
3. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study (4S): Lancet, 1994; 344:1383-1389
4. Forcheron F, Cachefo A, Thevenon S, Pinteur C, and Beylot M: Mechanisms of the triglyceride- and cholesterol-lowering effect of fenofibrate in hyperlipidemic type 2 diabetic patients. Diabetes, 2002; 51:3486-3491
5. Shepherd J: Does statin monotherapy address the multiple lipid abnormalities in type 2 diabetes? Atheroscler Suppl, 2005; 6:15-19
6. Powell E and Kroon P: LDL receptor and HMG CoA-reductase gene expression in human mononuclear leukocytes is regulated coordinately and parallels gene expression in liver. J Clin Invest, 1994; 93:2168-2174
7. Beylot M, Riou JP, Bienvenu F, and Mornex R: Increased ketonaemia in hyperthroidism: evidence for a beta-adrenergic mechanism. Diabetologia, 1980; 19:505-510
8. Kashyap ML: Mechanism studies of high-density lipoprotein. Am J Cardiol, 1998; 82:42-48
9. Harper CR and Jacobson TA: New perspectives on the management of low levels of high-density lipoprotein cholesterol. Arch Intern Med, 1999; 159:1049-1057
10. Segrest JP, Li L, Anantharamaiah GM, Harvey SC, Liadak KN, and Zannis V: Structure and function of apolipoprotein A-I and high-density lipoprotein. Curr Opin Lipidol, 2000; 11:106-115
11. Von Eckardstein A, Nofer J, and Assmann G: High density lipoproteins and arterisclerosis: Role of cholesterol efflux and reverse cholesterol transport. Arterioscler Thromb Vasc Biol, 2001; 21:13-17
12. Young S and Fielding C: The ABC's of cholesterol efflux. Nat Genet, 1999; 22:316-318
13. Trigatti BL, Rigotti A, and Braun A: Cellular and physiological roles of SR-BI, a lipoprotein receptor which mediates selective lipid uptake. Biochim Biophys Acta, 2000; 1529:276-286
14. Krieger M: Scavenger receptor class B type I is a multiligand HDL receptor that influences diverse physiologic systems. J Clin Invest, 2001; 108:793-797
15. Smart EJ, Graf GA, McNiven MA, Sessa WC, Engelman JA, Scherer PE, Okamoto T, and Lisanti MP: Caveolins, liquid-ordered domains, and signal transduction. Mol Cell Biol, 1999; 19:7289-7304
16. Fielding CJ and Fielding PE: Cholesterol and caveolae. structural and functional relationships. Biochim Biophys Acta, 2000; 1529:210-222
17. Nagano M, Yamashita S, Hirano K, Takano M, Maruyama T, Ishihara M, Sagehashi Y, Kujiraoka T, Tanaka K, Hattori H, Sakai N, Nakajima N, Egashira T, and Matsuzawa Y: Molecular mechanisms of cholesteryl ester transfer protein deficiency in Japanese. J Atheroscler Thromb, 2004; 11:110-121
18. Yamashita S, Arai T, Hirano K, Sakai N, Ishigami M, Nakajima N, and Matsuzawa Y: Molecular disorders of cholesteryl ester transfer protein. J Atheroscler Thromb, 1996; 3:1-11
19. Gordon DJ and Rifkind BM: High-density lipoproteins-the clinical implications of recent studies. N Engl J Med, 1989; 321:1311-1316
20. Goldbourt U, Yaaris S, and Medalie JH: Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality: A 21-year follow-up of 8000 men. Arterioscler Thromb Vasc Biol, 1997; 17:107-113
21. Hegele RA, Harris SB, Brunt JH, Young TK, Hanley AJ, and Zinman B: Absence of association between genetic variation in the LIPC gene promoter and plasma lipoproteins in three Canadian populations. Aterosclerosis, 1999; 146:153-160
22. Zhang B, Saku K, and Ohta T: In vivo metabolism of HDL, ApoA-I, and lp A-I, and function of HDL-a clinical perspective. J Atheroscler Thromb, 2000; 7:59-66
23. Duell PB, Oram JF, and Bierman EL: Nonenzymatic glycosylation of HDL and impaired HDL-receptor-mediated cholesterol efflux. Diabetes, 1991; 40:377-384
24. de Vries R, Groen A, Perton F, Dallinga-Thie G, van Wijland M, Dikkeschei L, Wolffenbuttel B, van Tol A, and Dullaart R: Increased cholesterol efflux from cultured fibroblasts to plasma from hypertriglyceridemic type 2 diabetic patients: Roles of pre β-HDL, phospholipid transfer protein and cholesterol esterification. Atherosclerosis, 2007; [Epub ahead of print] .
25. Mauldin JP, Srinivasan S, Mulya A, Gebre A, Parks JS, Daugherty A, and Hedrick CC: Reduction in ABCG1 in type 2 diabetic mice increases macrophage foam cell formation. J Biol Chem, 2006; 281:21216-21224
26. Brown MS and Goldstein JL: The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell, 1997; 89:331-340
27. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult treatment panel IIII): JAMA, 2001; 285:2486-2497
28. Tonkin A: High-density lipoprotein cholesterol and treatment guidelines. Am J Cardiol, 2001; 88:41-44
29. Lagrost L, Athias A, Lemort N, Richard JL, Desrumaux C, Chatenet-Duchene L, Courtois M, Farnier M, Jacotot B, Braschi S, and Gambert P: Plasma lipoprotein distribution and lipid transfer activities in patients with type IIb hyperlipidemia treated withsimvastatin. Atherosclerosis, 1999; 143:415-425
30. Ikewaki K, Rader DJ, Sakamoto T, Nishiwaki M, Wakimoto N, Schaefer JR, Ishikawa T, Fairwell T, Zech LA, and Nakamura H: Delayed catabolism of high density lipoprotein apolipoprotein A-I and A-II in human cholesteryl ester transfer protein deficiency. J Clin Invest, 1993; 92:1650-1658